Torrent Pharma Q4 FY26: A Margin Holding Pattern Amid JB Acquisition Turbulence

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Torrent posted ₹13,980 Cr in sales for FY26, up 21% YoY—a sharp acceleration that masks a Q4 stumble: Q4 sales hit ₹4,197 Cr (up 42% YoY), but net profit fell 21% QoQ to ₹364 Cr. That’s not a typo. The company acquired controlling stake in JB Chemicals mid-January and consolidated it from day 21 onwards, pushing Q4 numbers into territory that mingles Torrent’s stable ops with JB’s change-of-control volatility.

The operating margin held at 32% (operating profit ₹1,356 Cr in Q4), but tax jumped to 31% (from 22% in Q3), and the consolidated entity now carries ₹15,026 Cr in borrowings—a 369% leap from FY25. The market pays 69.5x earnings here; its own 5-year average sits at 27x.

Semaglutide launches are live in India (oral and injectable, March 2026). Brazil semaglutide awaits ANVISA but sits in a market where price erosion could strip 45–90% off first-launch pricing. Leverage is set to peak in FY27 at 2x net debt/EBITDA before deleveraging.

A balance sheet with a new megaton acquisition, a multiple with everything to prove, and a GLP-1 franchise that may print cash—or eat it.

2. Introduction

Torrent Pharmaceuticals ranks fifth in the Indian pharmaceutical market and holds fortress positions in chronic and sub-chronic therapies—cardiology, gastroenterology, CNS, diabetes. It’s a ₹1.52 Lakh Cr market-cap flagship of Torrent Group, which diversifies into power distribution and city gas.

The year to March 31, 2026 was transformational. In January, the board approved acquisition of JB Chemicals (46.39% stake) from KKR for ₹12,532 Cr, funded primarily through fresh debt. The mandatory open offer to public shareholders (26% stake) closed in December with minimal uptake. On March 24, the NCLT blessed the amalgamation scheme. FY26 results now include JB from January 21 onwards—three months of consolidated figures mixed into the annual print.

On the operational front, Torrent’s standalone pharma business grew methodically: domestic revenues benefited from volume outperformance in chronic therapies and 16,400+ reps in the field. The US generics franchise showed early green shoots after FDA warning letter resolution in 2023–2024. Germany remained disrupted by supplier regulatory issues, a problem seen as 3–4 quarters away from relief.

FY27 will be the first full year of the merged entity. The concall flagged ₹400–450 Cr in cost synergies over 2–3 years (20% in year 1, 80% in year 2).

3. Business Model: What Do They Even Do?

Torrent splits into two branded powerhouses: Branded Generics (74% of Q2 FY25 mix) and Generics (26%).

Branded Generics is the company’s spine. India accounts for ₹7,397 Cr (53% of FY24 revenue); Brazil contributes ₹1,065 Cr (10%); Germany ₹1,077 Cr (10%); rest of world fills the gaps. The portfolio hugs chronic and sub-chronic—cardiology, gastro, CNS, diabetes, vitamins, dermatology. Pricing in India remains sticky because the basket is positioned in therapies where price pressure is softer than commodity generics. Curatio, a new derma/OTC brand acquired in FY23, grew 27% in Q3 FY26 and is now in 72,000 retail outlets.

Generics peddles in the US, Europe, and emerging markets where patent exclusivity has expired. The US generics unit was comatose post-warning letters (Dahej and Indrad facilities). USFDA resolution in Aug 2023 and Aug 2024 unblocked new launches. Q3 FY26 US revenues hit $36m (constant currency, +12% YoY), still a fraction of the ₹150–160 Cr ($18–19m) run-rate management cited as “not happy with.” The target is $200m/year. Germany’s tender-driven generics business is in surgical pain—a third-party supplier’s regulatory tangle with EMA/FDA has crimped supply, causing Q3 FY26 EUR 29m constant currency, down 6% YoY.

On the innovation front: 780 scientists in R&D, ₹630 Cr spent in FY25 (5.5% of sales), 684 patents granted, 122 products in development. Eight manufacturing facilities in India with 2,500+ Cr unit dose capacity p.a. and 90 MTPA API capacity. Capex guidance: ₹250–300 Cr through FY27–FY28.

New Ventures launched oral oncology (Bileshwarpura, post-USFDA approval August 2023) and semaglutide mono and co-formulations (launched March 2026 at ₹3,999/month for injectable). JB acquisition adds significantly to the portfolio: ophthal in-licensed from Novartis, Asmarda (a portfolio of derma and oncology plays), and trade generics (management sees as structurally unattractive and plans to discontinue or fold into Torrent’s base).

4. Financials Overview

Figures are consolidated, in ₹ crore.

Q4 revenues spiked 42% YoY, driven by JB consolidation from Jan 21. Operating profit swelled 41% YoY, but tax hammered the bottom line: Q4 tax rate of 31% vs Q3’s 22%. Net profit collapsed 27% YoY and 43% QoQ—a reversal so sharp it warrants parsing.

Management’s concall (Feb 2026) disclosed a ₹45 Cr hedging loss booked into “other income” in Q3. Q4 also absorbed change-of-control adjustments in JB’s run-rate (management acknowledged potential “course correction” in Q4, with recovery expected from Q1 FY27 onwards). The message: strip out JB’s first three months of noise and Torrent’s underlying business is humming.

On an annualized basis, Q4 EPS of ₹10.76 translates to a reported earnings run-rate that is depressed by acquisition timing and FX hedging volatility. The full-year EPS of ₹63.92 (FY26 from annual data) is the cleaner metric.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 69.5x trailing earnings, a 2.6x premium to its own 5-year mean of 27x and 2.15x above the peer median of 32.2x. The EV/EBITDA of 37.6x